Amibegron
Encyclopedia
Amibegron is a drug developed by Sanofi-Aventis
which acts as a selective agonist for the β3 adrenergic receptor
. It is the first orally active β3 agonist developed that is capable of entering the Central Nervous System
, and has antidepressant
and anxiolytic
effects.
On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.
Sanofi-Aventis
Sanofi S.A. is a multinational pharmaceutical company headquartered in Paris, France, the world's fourth-largest by prescription sales. Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the...
which acts as a selective agonist for the β3 adrenergic receptor
Beta-3 adrenergic receptor
The beta-3 adrenergic receptor , also known as ADRB3, is an beta-adrenergic receptor, and also denotes the human gene encoding it.-Function:Actions of the β3 receptor include:*Enhancement of lipolysis in adipose tissue....
. It is the first orally active β3 agonist developed that is capable of entering the Central Nervous System
Central nervous system
The central nervous system is the part of the nervous system that integrates the information that it receives from, and coordinates the activity of, all parts of the bodies of bilaterian animals—that is, all multicellular animals except sponges and radially symmetric animals such as jellyfish...
, and has antidepressant
Antidepressant
An antidepressant is a psychiatric medication used to alleviate mood disorders, such as major depression and dysthymia and anxiety disorders such as social anxiety disorder. According to Gelder, Mayou &*Geddes people with a depressive illness will experience a therapeutic effect to their mood;...
and anxiolytic
Anxiolytic
An anxiolytic is a drug used for the treatment of anxiety, and its related psychological and physical symptoms...
effects.
On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.